Effects of sprint interval versus combined aerobic and resistance training in overweight women with type 2 diabetes

Effects of sprint interval versus combined aerobic and resistance training on adipokines, myokines and metabolic outcomes in overweight women with type 2 diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20141118019995N10

Enrollment

Registered

2017-12-04

Start date

2015-04-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes. Non-insulin-dependent diabetes mellitus

Interventions

Intervention 1: Intervention group 1: The SIT training group dose an exercise program on an cycle ergometers for 10 weeks. Each session consisted of a 5-minute warm-up, 4 × 30 seconds maximum intensit

Intervention group 1: The SIT training group dose an exercise program on an cycle ergometers for 10 weeks. Each session consisted of a 5-minute warm-up, 4 × 30 seconds maximum intensity intervals at b

Intervention group 2: The combined training (aerobic + resistance) do a training program for 10 weeks. Aerobic training progressed from 20 min/session at 50% maximum heart rate (HR) in week 1-2 to 30

Control group: The control group do not any regular physical activity in daily life.

Eligibility

Sex/Gender

Female

Age

45 Years to 60 Years

Inclusion criteria

Inclusion criteria: Female 45 - 60 years old with type 2 diabetes BMI>30 kg/m2 HbA1C = 6.5% Fasting blood glucose = 126 mg/dL Sedentary

Exclusion criteria

Exclusion criteria: Blood pressure = 160/100 mmHg Fasting triglyceride = 500 mg/dL A history of cardiovascular diseases, thyroid disorder, cancer, hormonal disorder, kidney and liver diseases Smoking, use of opioids, alcohol Doing regular exercise more than one year

Design outcomes

Primary

Measure	Time frame
IL-15. Timepoint: Before and after 10 weeks of intervention. Method of measurement: ELISA kit for IL-15.;SPARC. Timepoint: Before and after 10 weeks of intervention. Method of measurement: ELISA kit for SPARC.;Irisin. Timepoint: Before and after 10 weeks of intervention. Method of measurement: ELISA kit for Irisin.;FGF-21. Timepoint: Before and after 10 weeks of intervention. Method of measurement: ELISA kit for FGF-21.;ANGPTL4. Timepoint: Before and after 10 weeks of intervention. Method of measurement: ELISA kit for ANGPTL4.	—

Measure

Time frame

IL-15. Timepoint: Before and after 10 weeks of intervention. Method of measurement: ELISA kit for IL-15.;SPARC. Timepoint: Before and after 10 weeks of intervention. Method of measurement: ELISA kit for SPARC.;Irisin. Timepoint: Before and after 10 weeks of intervention. Method of measurement: ELISA kit for Irisin.;FGF-21. Timepoint: Before and after 10 weeks of intervention. Method of measurement: ELISA kit for FGF-21.;ANGPTL4. Timepoint: Before and after 10 weeks of intervention. Method of measurement: ELISA kit for ANGPTL4.

—

Secondary

Measure	Time frame
Weight. Timepoint: Before and after 10 weeks of intervention. Method of measurement: digital scale.;Body fat percent. Timepoint: Before and after 10 weeks of intervention. Method of measurement: Caliper.;Body Mass Index (BMI). Timepoint: Before and after 10 weeks of intervention. Method of measurement: Weight divided by height squared.;Fasting blood glucose. Timepoint: Before and after 10 weeks of intervention. Method of measurement: ELISA kit.;Ansulin. Timepoint: Before and after 10 weeks of intervention. Method of measurement: ELISA kit.;Insulin resistance. Timepoint: Before and after 10 weeks of intervention. Method of measurement: The insulin resistance index by the (HOMA-IR) formula.	—

Measure

Time frame

Weight. Timepoint: Before and after 10 weeks of intervention. Method of measurement: digital scale.;Body fat percent. Timepoint: Before and after 10 weeks of intervention. Method of measurement: Caliper.;Body Mass Index (BMI). Timepoint: Before and after 10 weeks of intervention. Method of measurement: Weight divided by height squared.;Fasting blood glucose. Timepoint: Before and after 10 weeks of intervention. Method of measurement: ELISA kit.;Ansulin. Timepoint: Before and after 10 weeks of intervention. Method of measurement: ELISA kit.;Insulin resistance. Timepoint: Before and after 10 weeks of intervention. Method of measurement: The insulin resistance index by the (HOMA-IR) formula.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Ebrahim Banitalebi

Shahrekord University

Banitalebi@lit.sku.ac.ir+98 38 3232 4401

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026